Small trial targeting Epstein-Barr infections shows promise as multiple sclerosis treatment - Medical Xpress
4/13/2022 12:00:00 AM3 yearsago
by Bob Yirka
by Bob Yirka
A team of researchers at Atara Biotherapeutics has conducted a small Phase I clinical trial of a therapeutic called ATA188 that targets Epstein-Barr infections (EBV) as a treatment for multiple sclerosis (MS). Representatives from Atara Biotherapeutics presen…
A team of researchers at Atara Biotherapeutics has conducted a small Phase I clinical trial of a therapeutic called ATA188 that targets Epstein-Barr infections (EBV) as a treatment for multiple scler… [+2608 chars]
full article...